ORIC Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ORIC) $8.27 +0.37 (+4.68%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$7.65▼$8.3050-Day Range$5.41▼$8.2752-Week Range$2.91▼$9.79Volume406,163 shsAverage Volume339,532 shsMarket Capitalization$451.13 millionP/E RatioN/ADividend YieldN/APrice Target$16.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability ORIC Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside96.9% Upside$16.29 Price TargetShort InterestBearish28.09% of Float Sold ShortDividend StrengthN/ASustainability-0.65Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.96) to ($2.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 starsMedical Sector543rd out of 950 stocksPharmaceutical Preparations Industry257th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingORIC Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.29, ORIC Pharmaceuticals has a forecasted upside of 96.9% from its current price of $8.27.Amount of Analyst CoverageORIC Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted28.09% of the float of ORIC Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverORIC Pharmaceuticals has a short interest ratio ("days to cover") of 20.3, which indicates bearish sentiment.Change versus previous monthShort interest in ORIC Pharmaceuticals has recently increased by 14.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldORIC Pharmaceuticals does not currently pay a dividend.Dividend GrowthORIC Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreORIC Pharmaceuticals has received a 73.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for ORIC Pharmaceuticals is -0.65. Previous Next 2.2 News and Social Media Coverage News SentimentORIC Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ORIC Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for ORIC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ORIC Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ORIC Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.34% of the stock of ORIC Pharmaceuticals is held by insiders.Percentage Held by Institutions91.30% of the stock of ORIC Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ORIC Pharmaceuticals are expected to decrease in the coming year, from ($1.96) to ($2.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ORIC Pharmaceuticals is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ORIC Pharmaceuticals is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioORIC Pharmaceuticals has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ORIC Pharmaceuticals Stock (NASDAQ:ORIC)ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Read More ORIC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORIC Stock News HeadlinesNovember 24, 2023 | americanbankingnews.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Buy" from AnalystsNovember 9, 2023 | morningstar.comORIC Pharmaceuticals Inc ORICDecember 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL), Oric Pharmaceuticals (ORIC) and Acadia Healthcare (ACHC)November 6, 2023 | msn.comORIC Pharmaceuticals GAAP EPS of -$0.44November 6, 2023 | finance.yahoo.comORIC Pharmaceuticals Inc (ORIC) Reports Q3 2023 Financial Results and Operational UpdatesNovember 6, 2023 | finance.yahoo.comORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational UpdatesNovember 2, 2023 | finance.yahoo.comORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 23, 2023 | msn.comWedbush Reiterates ORIC Pharmaceuticals (ORIC) Outperform RecommendationOctober 23, 2023 | markets.businessinsider.comAnalyst Expectations for ORIC Pharmaceuticals's FutureOctober 21, 2023 | finance.yahoo.comInitial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class ProfileOctober 17, 2023 | finance.yahoo.comORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023October 16, 2023 | finance.yahoo.comOric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?September 26, 2023 | finance.yahoo.comNextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhDSeptember 20, 2023 | benzinga.comORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare ConferenceSeptember 20, 2023 | finance.yahoo.comORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare ConferenceSeptember 13, 2023 | msn.comNavigating ORIC's Robust Strategy Against Cancer Drug ResistanceAugust 17, 2023 | markets.businessinsider.comOric Pharmaceuticals (ORIC) Receives a Buy from Robert W. BairdAugust 16, 2023 | msn.comBaird Maintains ORIC Pharmaceuticals (ORIC) Outperform RecommendationAugust 15, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)August 11, 2023 | msn.comMarkets Today: Stocks Fall on a Hot U.S. July PPIAugust 11, 2023 | msn.comORIC Pharmaceuticals GAAP EPS of -$0.50 beats by $0.08August 11, 2023 | finance.yahoo.comORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational UpdatesAugust 4, 2023 | finance.yahoo.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 28, 2023 | markets.businessinsider.comWhy Oric Pharmaceuticals Stock Is Shooting Higher TodayJune 26, 2023 | finance.yahoo.comWhy Shares of Oric Pharmaceuticals Jumped MondaySee More Headlines Receive ORIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORIC CUSIPN/A CIK1796280 Webwww.oricpharma.com Phone650-388-5600FaxN/AEmployees93Year FoundedN/APrice Target and Rating Average Stock Price Target$16.29 High Stock Price Target$27.00 Low Stock Price Target$13.00 Potential Upside/Downside+96.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.61% Return on Assets-35.85% Debt Debt-to-Equity RatioN/A Current Ratio12.26 Quick Ratio12.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.54 per share Price / Book1.82Miscellaneous Outstanding Shares54,550,000Free Float51,638,000Market Cap$451.13 million OptionableNot Optionable Beta0.88 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Richard A. Heyman Ph.D. (Age 66)Co-Founder, Independent Chairman & Member of Scientific Advisory Board Comp: $93kDr. Jacob M. Chacko M.B.A. (Age 44)M.D., President, CEO & Director Comp: $921.32kMr. Dominic G. Piscitelli CPA (Age 48)M.B.A., Chief Financial Officer Comp: $636.91kDr. Pratik S. Multani M.D. (Age 56)M.S., Chief Medical Officer Comp: $686.88kDr. Charles L. Sawyers B.A. (Age 64)M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Scott W. Lowe Ph.D.Co-Founder & Member of Scientific Advisory BoardDr. Lori Sickels Friedman Ph.D. (Age 59)Chief Scientific Officer Dr. Christian V. Kuhlen Esq. (Age 50)J.D., M.D., General Counsel Mr. Daniel IazzettiVP & Head of PeopleDr. Edna Chow Maneval (Age 63)Senior Vice President of Clinical Development More ExecutivesKey CompetitorsPhibro Animal HealthNASDAQ:PAHCAdlai NortyeNASDAQ:ANLPhathom PharmaceuticalsNASDAQ:PHATLyell ImmunopharmaNASDAQ:LYELSeelos TherapeuticsNASDAQ:SEELView All CompetitorsInsiders & InstitutionsEuclidean Capital LLCBought 241,860 shares on 12/1/2023Ownership: 1.814%American Century Companies Inc.Bought 13,477 shares on 11/30/2023Ownership: 0.059%Deutsche Bank AGBought 3,808 shares on 11/24/2023Ownership: 0.047%GSA Capital Partners LLPSold 85,472 shares on 11/15/2023Ownership: 0.062%AQR Capital Management LLCBought 11,199 shares on 11/15/2023Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions ORIC Stock Analysis - Frequently Asked Questions Should I buy or sell ORIC Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORIC shares. View ORIC analyst ratings or view top-rated stocks. What is ORIC Pharmaceuticals' stock price target for 2024? 7 equities research analysts have issued 12 month price targets for ORIC Pharmaceuticals' stock. Their ORIC share price targets range from $13.00 to $27.00. On average, they anticipate the company's stock price to reach $16.29 in the next year. This suggests a possible upside of 96.9% from the stock's current price. View analysts price targets for ORIC or view top-rated stocks among Wall Street analysts. How have ORIC shares performed in 2023? ORIC Pharmaceuticals' stock was trading at $5.89 at the start of the year. Since then, ORIC stock has increased by 40.4% and is now trading at $8.27. View the best growth stocks for 2023 here. When is ORIC Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our ORIC earnings forecast. How were ORIC Pharmaceuticals' earnings last quarter? ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its quarterly earnings results on Monday, November, 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.02. What other stocks do shareholders of ORIC Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG). When did ORIC Pharmaceuticals IPO? (ORIC) raised $75 million in an initial public offering on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities acted as the underwriters for the IPO. Who are ORIC Pharmaceuticals' major shareholders? ORIC Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Alkeon Capital Management LLC (6.38%), FMR LLC (5.74%), Silverarc Capital Management LLC (2.06%), Euclidean Capital LLC (1.81%), Vivo Capital LLC (1.43%) and Monaco Asset Management SAM (0.71%). Insiders that own company stock include Carl L Gordon, Dominic Piscitelli, Jacob Chacko, Orbimed Advisors Llc, Pratik S Multani, Richard A Heyman, Richard A Heyman and Richard H Scheller. View institutional ownership trends. How do I buy shares of ORIC Pharmaceuticals? Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ORIC) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.